



NEWS RELEASE

CareDx to Participate in Upcoming Healthcare Conferences in February 2016:

Leerink, BIO CEO & BTIG

Brisbane, CA — February 2, 2016—CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients today announced the Company's management will be participating in three upcoming investor conferences.

Peter Maag, PhD., Chief Executive Officer and President of CareDx, will be presenting at the Leerink Partners 5th Annual Global Healthcare Conference in New York City on February 10, 2016 at 6:15am PT/9:15am ET. A live audio webcast of the presentation will be available online from the investor relations page of the Company's website at <http://investors.caredxinc.com>. The webcast replay of the presentation will begin approximately one hour after the conclusion of the live presentation and will be available on the Company's website for 90 days.

CareDx management is also scheduled to participate in the 18th BIO CEO & Investor Conference in New York, NY on February 9, 2016 and the BTIG Third Annual Snowbird Medical Technology, Diagnostics, and Healthcare IT Conference in Snowbird, UT on February 24, 2016. Due to the one-on-one only format of these events, no webcast will be available.

About CareDx

CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. The company has commercialized AlloMap[®], a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure[™], its next-generation sequencing based test to detect donor-derived cell-free DNA after transplantation. For more information, please visit: www.CareDx.com.

Media Contact

Molly Martell, CareDx, Inc.
T: +1 415-287-2397

Investor Contact

Leigh J. Salvo, Westwicke Partners, LLC
T: +1 415-513-1281

Forward Looking Statements

This press release contains forward-looking statements including, but not limited to statements regarding the Company's expectations regarding future potential, development and commercial activities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward looking statements, including CareDx's limited operating history and experience with developing new markets; that closing conditions may not be satisfied and the transaction may not be completed; that the business acquired in the acquisition will not be integrated successfully; that the benefits of complementary product portfolios may not be realized; that products launched by the combined company will not be successfully commercialized or commercialization efforts may be slower than anticipated; that the combined company is not able to maintain current revenue levels; risk relating to new partnerships and commercialization of those relationships, as well as other risks stated in CareDx's filings with the SEC located at www.sec.gov. CareDx disclaims any obligation to publicly update or revise any forward looking statements to reflect events that occur or circumstances that exist after the date on which they were made.